Actos Articles
Tokyo pharma stocks - week to July 22
29 July 2002
Eli Lilly 2nd-qtr sales decrease 9%
29 July 2002
Tokyo pharma stocks - week to June 24
1 July 2002
Takeda to build bulk facility in Ireland
3 June 2002
Tokyo pharma stocks - week to May 13
20 May 2002
Tokyo pharma stocks - week to May 6
13 May 2002
Tokyo pharma stocks - week to April 22
29 April 2002
Takeda building new pharma bulk plant in Ireland
1 April 2002
Glitazones raising risk of heart failure?
1 April 2002
GSK files Avandia in Japan
18 February 2002
Tokyo pharma stocks - week to January 28
4 February 2002
Takeda and GSK win Pharma Marketing award
9 November 2001
Eli Lilly adding 5,000 more sales reps
26 October 2001
Tokyo stock comment; week to October 22
24 October 2001
Stock Commentary - Tokyo
18 October 2001
Japan pharma stock market - week to October 15
17 October 2001
GlaxoSmithKline warned over Avandia promotion by US FDA
6 August 2001
CORRECTION: Takeda's Actos
26 July 2001
Japan pharma stocks - week to July 23
25 July 2001
Novartis and Novo join to market NN622
23 July 2001
Stock Commentary - Tokyo
28 June 2001
Japan pharma stock market, week to June 25
27 June 2001
CORRECTION: Takeda's Actos
31 May 2001
Zyprexa takes over as Eli Lilly's top seller
26 January 2001
SB to take Indian firms to court over Avandia?
5 December 2000
Takeda correction
16 November 2000
Modernizing Merck KGaA looking to long-term growth from pharma
8 November 2000
Japan's Takeda posts net profits up 52% helped by sales abroad
7 November 2000
New products boost growth at Eli Lilly
20 October 2000
Stock Commentary Tokyo
19 October 2000
B-MS gets OK for Glucophage XR
18 October 2000
Stock Commentary Tokyo
12 October 2000
Takeda expands Irish plant
10 August 2000
B-MS gains FDA OK for Glucovance
4 August 2000
Eli Lilly's 2nd-qtr EPS increases 17%
25 July 2000
SB gains approval for Avandia in EU
18 July 2000
Stock Commentary Tokyo
13 July 2000
Takeda gets CPMP backing for Actos
7 July 2000
Takeda gets nod from EMEA for Actos
6 July 2000
ADA meeting - More data on Actos' lipid effects
14 June 2000
Takeda benefits from strong US showing
24 May 2000
Stock Commentary Tokyo
27 April 2000
Lilly and Ono link up for sivelestat critical care drug
18 April 2000
Earnings rise 18% at Eli Lilly
17 April 2000
Stock Commentary Tokyo
13 April 2000
Actos takes the lead in new prescriptions
13 April 2000
Stock Commentary Tokyo
6 April 2000
Stock Commentary Tokyo
3 April 2000
Stock Commentary Tokyo
23 March 2000
Abbott and Takeda sign deal for Actos
8 March 2000
SB's Avandia "leading the class" in the USA
13 January 2000
Busy year for NCEs as major new compound classes launched
6 January 2000
Stock Commentary Tokyo
9 December 1999
Stock Commentary Tokyo
2 December 1999
Takeda to launch Actos in Japan; $1bn drug?
2 December 1999
Takeda to launch Actos in Japan
29 November 1999
Merck KGaA's strong results suggests big not necessarily beautiful
19 November 1999
Eli Lilly suffers from poor Prozac sales
22 October 1999
SB rebuffs suggestion of Avandia toxicity
11 October 1999
Takeda licenses novel diabetes drug
11 October 1999
Stock Commentary New York
30 September 1999
Stock Commentary Tokyo
30 September 1999
Takeda's staff-cutting strategy more a vision than a concrete plan
20 September 1999
Stock Commentary New York
16 September 1999
2000 set to be a dramatic year for Japan's drug industry says Lehman
2 September 1999
Stock Commentary Tokyo
2 September 1999
Stock Commentary New York
2 September 1999
Stock Commentary Tokyo
19 August 1999
Novo Nordisk sales rise 13%, signs pact with Japan's Takeda
12 August 1999
Stock Commentary Tokyo
5 August 1999
Stock Commentary Tokyo
29 July 1999
Stock Commentary Tokyo
22 July 1999
SB sales increase 11% boosted by Avandia
21 July 1999
Takeda moves domestic capacity abroad
20 July 1999
- Novo Nordisk's diabetes drug Victoza produced 8% weight loss in Ph III obesity trial
- Alchemia and Merck Serono collaborate on HA-Irinotecan with Erbitux
- Positive new data on Novartis' Galvus in elderly type 2 diabetes patients
- Proposal to list Roche's Neulastim and Actemra in New Zealand
- Johnson & Johnson expects 10 NDA filings by 2017, saying pharma sector poised for growth
